ModerateVitamin K antagonist anticoagulants×Imidazole antifungal
Updated · Methodology
Mechanism
Miconazole inhibits the enzymes CYP2C9 and CYP3A4 (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and CYP2C9 is the main enzyme that metabolises acenocoumarol (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists miconazole among the imidazole derivatives that can potentiate acenocoumarol, including miconazole applied locally (AEMPS). The size of the effect depends on how much miconazole reaches the blood. Miconazole from the oral gel is absorbed: after 60 mg, peak plasma levels are 31–49 ng/mL and the half-life is 20–25 hours (oral gel SmPC, AEMPS). From a cream, less than 1% of the dose is absorbed (miconazole cream SmPC, AEMPS). The Spanish miconazole vaginal ovules also contain metronidazole, and the acenocoumarol SmPC lists metronidazole among the drugs that potentiate acenocoumarol as well (vaginal ovule SmPC; acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. Data exist only for warfarin. With miconazole oral gel, bleeding events have been reported, some of them fatal (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Bleeding and bruising have also been reported after topical, vaginal and oral miconazole (miconazole buccal tablet prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. The miconazole oral gel SmPC contraindicates the gel only with warfarin. It lists acenocoumarol among the oral anticoagulants that need caution with the gel: monitor the prothrombin time or other suitable anticoagulation tests closely and adjust the anticoagulant dose (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use miconazole creams and vaginal ovules cautiously with vitamin K antagonists, which include acenocoumarol. Monitor the anticoagulant effect carefully and titrate the dose. Explain the signs of bleeding to the patient and ask them to stop miconazole at once if these appear (miconazole cream and vaginal ovule SmPCs, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)
- AEMPS: Ficha técnica: Miconazol, óvulos vaginales (nº registro 50441), sección 4.4 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, miconazol con metronidazol, neomicina, polimixina B y centella asiática), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- FDA: ORAVIG (miconazole) buccal tablets prescribing information (2026)– FDA, DailyMed setid dc2427ff-e566-4b48-b289-9e51c011250a, Galt Pharmaceuticals, revisión 01/2026 (versión 3), secciones 7.1, 7.2 y 12.3
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.5 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026 (texto revisado 08/2025), secciones 4.2, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9